Business Wire

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services

Share

Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research.

For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This high level of harmonization enables the seamless transfer and sharing of methods across its multiple laboratory sites, allowing the analysis of hundreds of thousands of samples efficiently.

“Our extensive bioanalytical offerings are designed to support both standalone projects and Altasciences' integrated drug development solutions. Whether for preclinical or clinical studies, we provide tailored solutions to meet specific research needs. At Altasciences, we’re committed to facilitating every phase of the scientific journey with precision and care,” said Dr. Lynne Le Sauteur, Vice President of Laboratory Sciences at Altasciences.

Altasciences’ bioanalytical services are built around a comprehensive suite of capabilities tailored for both small and large molecules. Core offerings include drug quantification, metabolite and biomarker analysis, and immunogenicity testing, to support and advance a molecule from discovery to market.

Altasciences’ bioanalytical approach focuses on three core pillars: understanding and anticipating client needs as scientists, creating innovative solutions, and fostering collaboration through transparent communication. This client-centered approach has helped Altasciences build lasting partnerships, assisting clients in meeting complex regulatory standards while maintaining scientific rigor.

To promote Altasciences’ bioanalytical services from discovery to Phase IV, they recently launched Unveiling the Invisible, a video campaign that showcases how their bioanalytical solutions provide critical insights that unveil the invisible and drive the creation of innovative therapies.

View the fascinating video series here.

About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Altasciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241113252394/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI20.11.2025 15:17:00 CET | Press release

Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free - Owkin’s AI co-pilot for biology - for use by Paris-Saclay. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120130113/en/ K Pro Free will now be available to the entire Université Paris-Saclay community, and in particular teachers, researchers and doctoral students working in the biomedical sciences. The partnership includes workshops, training sessions and events designed to promote the discovery and adoption of K Pro Free, as well as the co-organization of communication and dissemination initiatives around the use of AI in health. In this way, the partnership will promote user training, but also enrich and continuously improve the co-pilot's models through feedback and use cases from the l’Université Paris-Saclay community. This partnership is part of Université Paris-Saclay’s strategy to integr

Frasca Advances Flight Training Technology with New Visual System Powered by Unreal Engine20.11.2025 15:05:00 CET | Press release

Frasca International, Inc., a FlightSafety International company and leader in flight simulation, today announced the launch of VITAL FVS 100, the next evolution of its visual system technology. Building on the proven TruVision Global platform, VITAL FVS 100 was developed using Epic Games’ Unreal Engine and delivers unprecedented realism, scalability, and innovation in pilot training. The Unreal-powered VITAL FVS 100 system introduces major advancements in visual fidelity and training realism, further enhancing the capabilities of Frasca, a leading developer of flight simulators and training devices. The new system includes physically based renderings, advanced lighting effects, and a new volumetric cloud model that creates dynamic, weather-rich environments. Terrain imagery now includes one-meter resolution coverage for the contiguous United States and Hawaii, with expanded global datasets covering European buildings and tree covered regions. Additionally, enhanced particle effects re

GigaOm Radar for Vector Databases v3 Positions Vespa.ai as a Leader and Outperformer20.11.2025 15:00:00 CET | Press release

Vespa Recognized for Integrated Ranking, Multimodal Search, and Production-Scale AI Performance Vespa.ai, the creator of the AI Search Platform for building and deploying large-scale, real-time AI applications powered by big data, today announced its recognition as a Leader and Outperformer in the GigaOm Radar for Vector Databases v3, marking the company’s third consecutive year being evaluated in GigaOm’s vector database research. Now in its third edition, the report compares 17 leading open source and commercial solutions using GigaOm’s structured evaluation framework. In addition to core table-stakes capabilities, the Radar reviews each vendor’s key features, emerging strengths, and broader business criteria. The shift from Sonar to Radar reflects the technology’s transition into mainstream adoption. GigaOm names Vespa.ai a leader for its ability to manage complex data, optimize results at scale, and support multimodal AI workloads. The report highlights Vespa’s native tensor suppor

Hitit Empowers Airlines to Optimize Crew Leave Planning with Gurobi20.11.2025 15:00:00 CET | Press release

With Crane Crew, one of the products in Hitit’s Crane Solution Suite, dozens of airlines have reduced their planning periods from weeks to minutes. Gurobi Optimization, LLC, the leader in decision intelligence technology, is proud to be the solver of choice for Hitit, a leading global provider of airline and travel IT solutions. Hitit’s Crane Crew Leave Optimizer—one of the key sub-modules of Hitit’s Crane Crew solution—enables airlines to quickly generate optimal leave schedules for thousands of crew members. Powered by Gurobi’s mathematical optimization solver, the tool significantly reduces planning time while improving both operational efficiency and crew satisfaction. Among the many constraints that airlines must consider are operational requirements, business rules, crew seniority, and personal preferences. As such, manual planning efforts can often lead to inefficiencies, crew dissatisfaction, and compliance risks. After switching to Crane Crew, Hitit’s partner airlines have rep

Myonex Appoints Greg Lavin as Chief Executive Officer20.11.2025 15:00:00 CET | Press release

Greg Lavin takes over the CEO role as James Lovett retires and joins the company’s Board of Directors Myonex®, a leading global integrated clinical trial supply solutions and commercial services company, announced today that Greg Lavin, Chief Financial Officer (CFO), will assume the role of Chief Executive Officer (CEO) effective January 1, 2026. A seasoned executive with experience in the pharmaceutical services industry, including senior roles across clinical research organizations, preclinical and laboratory services, and healthcare data analysis, Lavin succeeds James Lovett, who is retiring and will remain on the company’s board of directors to provide strategic guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120250133/en/ Greg Lavin at Myonex's Headquarters in Horsham, PA During his 6-plus years as CFO of Myonex, Lavin has worked closely with Lovett in driving its transformation from a comparator sourcing su

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye